CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to identify and validate genes that can reverse T cell dysfunction in cancer, which is crucial for improving immunotherapy effectiveness. Using CRISPR-Cas9 screening, the research focuses on understanding the mechanisms behind T cell dysfunction and testing potential therapeutic targets in both mouse a…
T cell dysfunction is a key problem in cancer, enabling not only tumorigenesis but also causing resistance to immunotherapy.
Induction of immune checkpoints is a hallmark of T cell dysfunction, but clinical blockade by PD-1 and CTLA-4 antibodies solves this problem for few patients only.
Dysfunction is driven also by additional mechanisms, including chronic stimulation and metabolic insufficiency. A better mechanistic understanding will be imperative for improving immunotherapy.
My laboratory r…
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
